Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core Operating Income Growth at Constant Currencies by Quarter
Core Operating Income Growth at Constant Currencies (% cc) (%)
Novartis Core Operating Income Growth at Constant Currencies: 10.0% in Q3 2026, up 3.0 pts from a year earlier.
Latest, Q3 2026
10.0%
Period ended Sep 30, 2026
Change on a year earlier
+3.0 pts
7.0% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“|| Core operating income | 6 036 | 5 460 | 11 | 10 | 16 873 | 16 960 | -1 | -2”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Operating Income Growth at Constant Currencies (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 10.0% | +3.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 0.0% | -21.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | -14.0% | -41.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 1.0% | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 7.0% | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 21.0% | – | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 27.0% | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
Cite this data
StockData. (2026). Novartis Core Operating Income Growth at Constant Currencies (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-opinc-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.